Tandem Diabetes Care (TNDM) EBT Growth (1y) (2014 - 2026)
Tandem Diabetes Care (TNDM) EBT Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | -18.50% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 11.26% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -8.83% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 44.35% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 5.78% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 103.34% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 74.66% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | -27.02% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 54.33% |
| 10 | Tandem Diabetes Care | 1.04 Bn | 474.17 Mn | 136.79 Mn | 83.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83.72% |
| Dec 31, 2025 | 15,660.00% |
| Sep 30, 2025 | -11.18% |
| Jun 30, 2025 | -94.07% |
| Mar 31, 2025 | -208.86% |
| Dec 31, 2024 | 100.10% |
| Sep 30, 2024 | 26.34% |
| Jun 30, 2024 | 14.04% |
| Mar 31, 2024 | 68.01% |
| Dec 31, 2023 | -94.58% |
| Sep 30, 2023 | 35.16% |
| Jun 30, 2023 | -167.18% |
| Mar 31, 2023 | -653.57% |
| Dec 31, 2022 | -245.16% |
| Sep 30, 2022 | -909.66% |
| Jun 30, 2022 | -418.26% |
| Mar 31, 2022 | -217.77% |
| Dec 31, 2021 | -34.85% |
| Sep 30, 2021 | 162.42% |
| Jun 30, 2021 | 113.94% |